MultiCorp International, Inc. to Develop 4 Arm Study for Emergency Room Clinical Trials With Patented Migraine Medicine

MultiCorp International, Inc. (OTCPINK:MCIC) announced that a it received a report from the U.S. Food and Drug Administration giving the company specific guidelines in creating a 4 arm study to administer the patented migraine medicine in an emergency room setting.
According to the company:

The company has received a detailed response to the Pre-IND submission sent to the U.S. Food and Drug Administration for the further development of the patented migraine medicine the company has ownership in. The FDA has responded in supplying the company with a clear roadmap to develop a 4 arm study wherein the medicine will be dispensed in an emergency room setting for patients that enter the ER for migraine relief. This study will give the company feedback on the efficacy of the drug as compared to other medications currently being dispensed to relieve migraines. This study significantly will speed up the process to bring the product to market.

Click here to view the full press release.